1887

Abstract

Brunenders, a type I poliovirus (PV) strain, was developed in 1952 by J. F. Enders and colleagues through serial passaging of the parental Brunhilde strain, and was reported to display partial neuroattenuation in monkeys. This phenotype of attenuation encouraged two vaccine manufacturers to adopt Brunenders as the type I component for their inactivated poliovirus vaccines (IPVs) in the 1950s, although today no licensed IPV vaccine contains Brunenders. Here we confirmed, in a transgenic mouse model, the report of Enders on the reduced neurovirulence of Brunenders. Although dramatically neuroattenuated relative to WT PV strains, Brunenders remains more virulent than the attenuated oral vaccine strain, Sabin 1. Importantly, the neuroattenuation of Brunenders does not affect growth kinetics and antigenicity, which were similar to those of Mahoney, the conventional type I IPV vaccine strain. We showed, by full nucleotide sequencing, that Brunhilde and Brunenders differ at 31 nucleotides, eight of which lead to amino acid changes, all located in the capsid. Upon exchanging the Brunenders capsid sequence with that of the Mahoney capsid, WT neurovirulence was regained , suggesting a role for the capsid mutations in Brunenders attenuation. To date, as polio eradication draws closer, the switch to using attenuated strains for IPV is actively being pursued. Brunenders preceded this novel strategy as a partially attenuated IPV strain, accompanied by decades of successful use in the field. Providing data on the attenuation of Brunenders may be of value in the further construction of attenuated PV strains to support the grand pursuit of the global eradication of poliomyelitis.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.000197
2015-09-01
2019-10-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/96/9/2614.html?itemId=/content/journal/jgv/10.1099/vir.0.000197&mimeType=html&fmt=ahah

References

  1. Beale J.A. . ( 2011;). The development of IPV. . In History of Vaccine Development, pp. 179–187. Edited by Plotkin S. A. . New York: [CrossRef] Springer;.
    [Google Scholar]
  2. Belnap D.M. , McDermott B.M. Jr , Filman D.J. , Cheng N. , Trus B.L. , Zuccola H.J. , Racaniello V.R. , Hogle J.M. , Steven A.C. . ( 2000;). Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc Natl Acad Sci U S A 97: 73–78 [PubMed].[CrossRef]
    [Google Scholar]
  3. Bodian D. , Morgan I.M. , Howe H.A. . ( 1949;). Differentiation of types of poliomyelitis viruses; the grouping of 14 strains into three basic immunological types. Am J Hyg 49: 234–245 [PubMed].
    [Google Scholar]
  4. Borzakian S. , Pelletier I. , Calvez V. , Colbere-Garapin F. . ( 1993;). Precise missense and silent point mutations are fixed in the genomes of poliovirus mutants from persistently infected cells. J Virol 67: 2914–2917 [PubMed].
    [Google Scholar]
  5. Böttiger M. . ( 1990;). Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 8: 443–445 [CrossRef] [PubMed].
    [Google Scholar]
  6. Bouchard M.J. , Lam D.H. , Racaniello V.R. . ( 1995;). Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 69: 4972–4978 [PubMed].
    [Google Scholar]
  7. Coid C.R. , Beswick T.S. . ( 1960;). Production of viraemia in cortisone-treated monkeys with the attenuated Brunenders strain of type-I poliovirus. Lancet 275: 414–415 [CrossRef] [PubMed].
    [Google Scholar]
  8. Coid C.R. , Tobin J.O. , Beswick T.S. . ( 1960;). The sensitivity of monkeys to subcutaneous inoculation of the Brunenders strain of type-I poliomyelitis virus. J Pathol Bacteriol 79: 325–330 [CrossRef] [PubMed].
    [Google Scholar]
  9. Coid C.R. , Beswick T.S. , Tobin J.O. . ( 1961;). The virulence of strains of poliovirus for cynomologus monkeys after subcutaneous injection. J Hyg (Lond) 59: 387–394 [PubMed].[CrossRef]
    [Google Scholar]
  10. Day A. . ( 2009;). ‘An American tragedy’. The Cutter incident and its implications for the Salk polio vaccine in New Zealand 1955–1960. Health History 11: 42–61 [PubMed].
    [Google Scholar]
  11. Enders J.F. , Weller T.H. , Robbins F.C. . ( 1952;). Alteration in pathogenicity for monkeys of Brunhilde strain of poliomyelitis virus following cultivation in human tissues. Fed Proc 11: 467.
    [Google Scholar]
  12. Evans D.G. , Beswick T.S.L. , Coid C.R. , Ferguson A.J. , Perkins F.T. , Petts A. , Russell K. , Tobin J.O'H , Yetts R. . ( 1957;). Safety and antigenic potency testing of poliomyelitis vaccine; a report from the Biological Standards Control Laboratory, Medical Research Council Laboratories, London, N.W.3. Br Med J 2: 124–126.[CrossRef]
    [Google Scholar]
  13. Gear J. . ( 1956;). The South African poliomyelitis vaccine. S Afr Med J 30: 587–594 [PubMed].
    [Google Scholar]
  14. He Y. , Mueller S. , Chipman P.R. , Bator C.M. , Peng X. , Bowman V.D. , Mukhopadhyay S. , Wimmer E. , Kuhn R.J. , Rossmann M.G. . ( 2003;). Complexes of poliovirus serotypes with their common cellular receptor, CD155. J Virol 77: 4827–4835 [CrossRef] [PubMed].
    [Google Scholar]
  15. Koike S. , Taya C. , Kurata T. , Abe S. , Ise I. , Yonekawa H. , Nomoto A. . ( 1991;). Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci U S A 88: 951–955 [CrossRef] [PubMed].
    [Google Scholar]
  16. Macadam A.J. , Pollard S.R. , Ferguson G. , Skuce R. , Wood D. , Almond J.W. , Minor P.D. . ( 1993;). Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192: 18–26 [CrossRef] [PubMed].
    [Google Scholar]
  17. Martín J. , Minor P.D. . ( 2002;). Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. J Virol 76: 5339–5349 [CrossRef] [PubMed].
    [Google Scholar]
  18. Martín J. , Crossland G. , Wood D.J. , Minor P.D. . ( 2003;). Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 84: 1781–1788 [CrossRef] [PubMed].
    [Google Scholar]
  19. Minor P.D. . ( 1986;). Antigenic structure of poliovirus. Microbiol Sci 3: 141–144 [PubMed].
    [Google Scholar]
  20. Minor P.D. , Ferguson M. , Evans D.M. , Almond J.W. , Icenogle J.P. . ( 1986;). Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol 67: 1283–1291 [CrossRef] [PubMed].
    [Google Scholar]
  21. Minor P.D. , Macadam A.J. , Stone D.M. , Almond J.W. . ( 1993;). Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals 21: 357–363 [CrossRef] [PubMed].
    [Google Scholar]
  22. Nathanson N. , Langmuir A. . ( 1963;). The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United Sates during the spring of 1955. III. Comparison of clinical character of vaccinated and contact cases occurring after use of high rate lots of Cutter Vaccine. Am J Hyg 78: 61–81.
    [Google Scholar]
  23. Nicholson R. , Pelletier J. , Le S.Y. , Sonenberg N. . ( 1991;). Structural and functional analysis of the ribosome landing pad of poliovirus type 2: in vivo translation studies. J Virol 65: 5886–5894 [PubMed].
    [Google Scholar]
  24. Offit P. . ( 2005;). What went wrong at Cutter Laboratories. . In The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis, pp. 105 New Haven, CT: Yale University Press;.
    [Google Scholar]
  25. Pliaka V. , Kyriakopoulou Z. , Markoulatos P. . ( 2012;). Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 11: 609–628 [CrossRef] [PubMed].
    [Google Scholar]
  26. Reed L.J. , Muench H. . ( 1938;). A simple method of estimating fifty per cent endpoint. Am J Hyg 27: 493–497.
    [Google Scholar]
  27. Ren R.B. , Moss E.G. , Racaniello V.R. . ( 1991;). Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 65: 1377–1382 [PubMed].
    [Google Scholar]
  28. Rieder E. , Paul A.V. , Kim D.W. , van Boom J.H. , Wimmer E. . ( 2000;). Genetic and biochemical studies of poliovirus cis-acting replication element cre in relation to VPg uridylylation. J Virol 74: 10371–10380 [CrossRef] [PubMed].
    [Google Scholar]
  29. Sabin A.B. . ( 1955a;). Behavior of chimpanzee avirulent poliomyelitis viruses in experimentally infected human volunteers. Am J Med Sci 230: 1–8 [CrossRef] [PubMed].
    [Google Scholar]
  30. Sabin A.B. . ( 1955b;). Immunization of chimpanzees and human beings with avirulent strains of poliomyelitis virus. Ann N Y Acad Sci 61: 1050–1056 [CrossRef] [PubMed].
    [Google Scholar]
  31. Sabin A.B. . ( 1957;). Properties and behavior of orally administered attenuated poliovirus vaccine. J Am Med Assoc 164: 1216–1223 [CrossRef] [PubMed].
    [Google Scholar]
  32. Sabin A.B. , Boulger L.R. . ( 1973;). History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1: 115–118.[CrossRef]
    [Google Scholar]
  33. Salk J.E. . ( 1953;). Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc 151: 1081–1098 [PubMed].[CrossRef]
    [Google Scholar]
  34. Sanders B.P. , Edo-Matas D. , Custers J.H. , Koldijk M.H. , Klaren V. , Turk M. , Luitjens A. , Bakker W.A. , Uytdehaag F. , other authors . ( 2013;). PER.C6®cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine. Vaccine 31: 850–856 [CrossRef] [PubMed].
    [Google Scholar]
  35. Shiroki K. , Ishii T. , Aoki T. , Ota Y. , Yang W.X. , Komatsu T. , Ami Y. , Arita M. , Abe S. , other authors . ( 1997;). Host range phenotype induced by mutations in the internal ribosomal entry site of poliovirus RNA. J Virol 71: 1–8 [PubMed].
    [Google Scholar]
  36. Song Y. , Liu Y. , Ward C.B. , Mueller S. , Futcher B. , Skiena S. , Paul A.V. , Wimmer E. . ( 2012;). Identification of two functionally redundant RNA elements in the coding sequence of poliovirus using computer-generated design. Proc Natl Acad Sci U S A 109: 14301–14307 [CrossRef] [PubMed].
    [Google Scholar]
  37. SSI ( 2014;). Description of VeroPol IPV Vaccine SSI Copenhagen: Statens Serum Institute; http://www.ssi.dk/English/Vaccines/VeroPol.aspx.
    [Google Scholar]
  38. van der Werf S. , Bradley J. , Wimmer E. , Studier F.W. , Dunn J.J. . ( 1986;). Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase. Proc Natl Acad Sci U S A 83: 2330–2334 [PubMed].[CrossRef]
    [Google Scholar]
  39. Verdijk P. , Rots N.Y. , van Oijen M.G. , Weldon W.C. , Oberste M.S. , Okayasu H. , Sutter R.W. , Bakker W.A. . ( 2014;). Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine 32: 4938–4944 [CrossRef] [PubMed].
    [Google Scholar]
  40. Westrop G.D. , Wareham K.A. , Evans D.M. , Dunn G. , Minor P.D. , Magrath D.I. , Taffs F. , Marsden S. , Skinner M.A. , other authors . ( 1989;). Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 63: 1338–1344 [PubMed].
    [Google Scholar]
  41. WHO ( 2002;). Recommendations for the production and control of poliomyelitis vaccine (inactivated). . In Technical Report Series No. 910 Geneva: World Health Organization;.
    [Google Scholar]
  42. Zuker M. . ( 2003;). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406–3415.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.000197
Loading
/content/journal/jgv/10.1099/vir.0.000197
Loading

Data & Media loading...

Supplements

Supplementary Data



PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error